FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|August 24, 2022
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of August 24, 2022
Author(s)Sydney Jennings
Advertisement
US COVID-19 vaccination & booster dose status
US COVID-19 vaccination status according to the Centers for Disease Control and Prevention (CDC) as of August 18, 2022, at 6:00 AM, EDT:
Fully vaccinated plus 2 booster doses:
• Aged ≥50 years 33.2%
• Aged ≥65 years 40.4%
Fully vaccinated plus 1 booster dose:
• Total US population 48.4%
Fully vaccinated in key age groups:
• Total US population 67.4%
• Aged ≥5 years 71.5%
• Aged ≥65 years 92%
US confirmed cases of COVID-19 and deaths
Confirmed US cases of COVID-19 and related deaths according to the Johns Hopkins COVID-19 interactive map , as of August 24, 2022 at 4:20 PM, EDT.
3 states with highest number of new cases in past 28 days
• California 375 293
• Texas 279 254
• Florida 223 183
• Total US confirmed cases 93 873 818
• Total US confirmed deaths 1 042 181
Global total COVID-19 confirmed cases, deaths, vaccine doses administered:
• Cases 598 322 602
• Deaths 6 460 868 • Vaccine doses administered 12 084 042 745
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
2
9 Drugs Approved for Primary Care: Q3 2026
3
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
4
FDA Clears IDE for NeuWire Medical's STROKE-REWIRE Trial in Chronic Ischemic Stroke
5